Ocrevus patent expiry uk?

See the DrugPatentWatch profile for Ocrevus

When Does Ocrevus Patent Expire in the UK?

Ocrevus, a multiple sclerosis treatment developed by Roche, has been a game-changer for patients with this chronic condition. However, the patent for the drug has not expired yet, and we need to explore the timeline for the UK.

What Is the Current Patent Status of Ocrevus?

According to DrugPatentWatch.com [1], the Ocrevus patent (EP3314448B1) is set to expire in May 2035 in the European Economic Area (EEA). However, as the UK has left the EEA, there are specific differences to consider.

UK Patent Exclusivity Timeline

Under the UK's patent law, Roche, the manufacturer, retains exclusivity for a period of up to 10 years from the initial patent grant date. This would place the UK patent expiry date sometime after May 2035. We'll need to wait for the UK patent grant to be processed for an exact date.

Impact on Availability and Pricing in the UK

While the patent doesn't expire immediately in the UK, the situation might become clearer once the UK patent grant is final. This could lead to increased competition and reduced prices for Ocrevus in the years to come.

Competitors and Biosimilars

Regeneron Pharmaceuticals has been granted a conditional marketing authorization in the UK for its multiple sclerosis treatment Sarclisa. However, Sarclisa is not a biosimilar of Ocrevus, so there is still significant competition in the field as more treatments come to market.

Regulatory Environment and Market Developments

The UK's National Institute of Health and Care Excellence (NICE) and the Medicines and Healthcare products Regulatory Agency (MHRA) closely monitor new treatments and biosimilars coming onto the market. Their appraisals will greatly influence the Ocrevus patent expiry and market situation in the UK.

Sources:

[1] DrugPatentWatch.com - Ocrevus (Ocrelizumab) patent EP3314448B1.